Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Current Deferred Revenue data on file, last reported at $33.0 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 91.2% year-over-year to $33.0 million in Q1 2026; TTM through Mar 2026 was $33.0 million, a 91.2% increase from a year earlier, with the FY2025 full-year figure at $27.2 million, up 37.78% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $33.0 million, up from $27.2 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for PHAT reached as high as $33.0 million in Q1 2026 and fell as low as $276000.0 in Q2 2023.
• Historically, Current Deferred Revenue has averaged $16.6 million across 4 years, with a median of $18.5 million in 2024.
• Across the five-year window, Current Deferred Revenue surged 3490.58% in 2024 and climbed 4.79% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $7.1 million in 2023, then jumped by 178.12% to $19.8 million in 2024, then surged by 37.78% to $27.2 million in 2025, then rose by 21.16% to $33.0 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $33.0 million in Q1 2026, $27.2 million in Q4 2025, and $24.3 million in Q3 2025.